Richard A. Young Sells 34,837 Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Stock

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Richard A. Young sold 34,837 shares of the firm’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $5.12, for a total transaction of $178,365.44. Following the completion of the sale, the director now owns 8,000 shares in the company, valued at $40,960. The sale was disclosed in a document filed with the SEC, which is available at this link.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS traded up $0.09 during midday trading on Tuesday, hitting $5.02. 45,801 shares of the company were exchanged, compared to its average volume of 174,307. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.01 and a quick ratio of 3.01. Syros Pharmaceuticals, Inc. has a fifty-two week low of $2.09 and a fifty-two week high of $8.17. The company has a fifty day simple moving average of $5.30 and a 200 day simple moving average of $6.09.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.79) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.10. Syros Pharmaceuticals had a negative net margin of 1,656.34% and a negative return on equity of 395.36%. During the same period last year, the firm earned ($0.85) EPS. Research analysts expect that Syros Pharmaceuticals, Inc. will post -3.19 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Piper Sandler reiterated an “overweight” rating and set a $13.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, April 3rd. StockNews.com upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, June 26th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in Syros Pharmaceuticals in the first quarter valued at $64,000. Acadian Asset Management LLC acquired a new position in Syros Pharmaceuticals in the first quarter valued at $91,000. Assenagon Asset Management S.A. boosted its holdings in shares of Syros Pharmaceuticals by 576.5% in the first quarter. Assenagon Asset Management S.A. now owns 169,999 shares of the company’s stock valued at $909,000 after acquiring an additional 144,869 shares in the last quarter. Opaleye Management Inc. purchased a new stake in shares of Syros Pharmaceuticals in the fourth quarter valued at about $2,799,000. Finally, Kennedy Capital Management LLC purchased a new stake in shares of Syros Pharmaceuticals in the first quarter valued at about $2,166,000. 91.47% of the stock is currently owned by institutional investors and hedge funds.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.